Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as GBX 28 and last traded at GBX 28, with a volume of 5,350 shares traded. The stock had previously closed at GBX 29.
Faron Pharmaceuticals Oy Stock Down 3.4%
The firm’s fifty day simple moving average is GBX 33.98 and its two-hundred day simple moving average is GBX 46.62. The company has a current ratio of 2.40, a quick ratio of 1.09 and a debt-to-equity ratio of 154.15. The company has a market capitalization of £56.81 million, a price-to-earnings ratio of -2.43 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Read More
- Five stocks we like better than Faron Pharmaceuticals Oy
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
